Top

Avivagen Inc.

TSXV Exchange | Feb 20, 2020, 1:39 PM EST | Real-time price

VIV $ 0.68 RT
CHANGE
-0.01 (-1.4493%)
VOLUME
5,500
Day Low: 0.67
Day High: 0.70
 Back
Avivagen Announces Closing of Additional $1.75 Million Private Placement

OTTAWA, Ontario

Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, is pleased to announce the successful second and final closing of its previously announced non-brokered private placement (the “Offering”). In connection with this final closing Avivagen has issued 3,500,000 units (the “Units”) at an issue price of $0.50 per Unit for aggregate gross proceeds to the Company of $1,750,000. With the proceeds of the first closing which occurred on January 2, 2020, this closing brings the total gross proceeds of the Offering to $3,000,000 for the sale of 6,000,000 Units.

Each Unit consists of one common share and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder to acquire one common share at $0.75 for a period of 3 years from closing.

In connection with the second closing of the Offering, Avivagen paid cash finder’s fees of $94,620 and issued 189,240 finders warrants, in the aggregate, to Haywood Securities Inc., Raymond James Ltd., Canaccord Genuity Corp., Echelon Wealth Partners, Leede Jones Gable Inc. and Richardson GMP. Each warrant issued to the finders entitles the holder to purchase one Unit at $0.50 per Unit for a period of 2 years. The Units issuable on exercise of the finders warrants are the same as the Units issued to subscribers the Offering except that each whole Warrant underlying the finder Units will be exercisable only during the period ending 2 years from closing of the Offering.

In connection with this second closing, the Company has agreed that the 200,000 finders warrants issued to finders in connection with the January 2, 2020 closing, as described in the Company’s press release dated January 3, 2020, shall be deemed to be on the same terms as those described above.

The Company plans to use the net proceeds from the Offering for product development and commercialization expenditures, working capital and for general corporate purposes.

All securities issued in connection with this second closing are subject to restrictions on transfer, including a hold period ending May 28, 2020. Final approval of the Offering is subject to filing customary documents with the TSX Venture Exchange.

About Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colours, and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently available for sale in the United States, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements about the use of proceeds and about the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as growth promoters are forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, circumstances may require that Avivagen apply the net proceeds of the Offering differently than anticipated or Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics as growth promoters in livestock feeds due to many factors, many of which are outside of Avivagen’s control. Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen’s most recent management’s discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright © 2020 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.

Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733
E-mail: d.basek@avivagen.com

Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164
Website: www.avivagen.com

Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. View delay times for all exchanges. Market Data powered by QuoteMedia. See the QuoteMedia Terms of Use.